Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Marker for predicting bladder cancer chemosensitivity and application

A marker and sensitivity technology, applied in the biological field, can solve the problems of patients and medical workers suffering from chemotherapy resistance, no solution, and the inability to guarantee the accuracy of predicting patients' chemotherapy sensitivity, so as to improve the clinical treatment effect , good application value and prospect effect

Inactive Publication Date: 2019-11-08
昆明医科大学第二附属医院
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Gemcitabine has been widely used clinically as a first-line chemotherapy drug for bladder cancer, but the emergence of chemotherapy resistance still plagues the majority of patients and medical workers.
[0004] Existing technologies often have large deviations through the detection of single molecular pathological indicators, and cannot guarantee the accuracy of predicting patients' chemotherapy sensitivity
How to better predict the sensitivity of bladder cancer patients to chemotherapy drugs, so as to provide support for clinicians to quickly and accurately understand the curative effect of bladder cancer patients on chemotherapy drugs, and to take more individualized prevention and treatment programs in a timely manner, there is no effective solution at present.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker for predicting bladder cancer chemosensitivity and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Select 20 cases of gemcitabine-resistant bladder cancer chemotherapy-resistant patients and gemcitabine-sensitive bladder cancer chemotherapy-sensitive patients, and perform quantitative PCR on the cancer and adjacent tissues of each patient to detect the abnormal expression of SOCS1 in chemotherapy-resistant patients in the previous study. , CYLD, HMGB1 and Ciap-1 gene levels, real-time quantitative PCR reaction using ProQPCR SuperMix

[0017] (Biochain) kit, each group set up 3 duplicate wells, using the cDNA of 40 patients' cancer tissues and para-cancer tissues as templates, and GADPH as an internal reference, to detect SOCS1, CYLD, and HMGB1 in cancer and para-cancer tissues of each patient. And the expression level of Ciap-1, and the ratio of the relative content of cancer and paracancerous tissue (O△Ct) as the expression difference ratio of the gene in patients, the experimental data is carried out through the IQ5Multicolor Real-time PCR Detection System (Hercules...

Embodiment 2

[0027] Example 2 Application of Biomarkers in Predicting Patients with Bladder Cancer Chemotherapy Resistance

[0028] A total of 80 patients with bladder cancer were selected, and real-time quantitative PCR (q-PCR) was used to detect the relative levels of bladder cancer Ciap-1 and SOCS1D mRNA in cancer and adjacent tissues (OCt). O△Ct) was used as the expression difference ratio of the gene in patients to predict the patient's resistance to gemcitabine.

[0029] Real-time quantitative PCR was used to detect the difference ratio of Ciap-1 and SOCS1 gene expression in cancer or paracancerous tissues of patients. ROC curve analysis showed that the areas under the ROC line of Ciap-1 and SOCS1 were 0.8214 and 0.8731, respectively. The predicted area under the curve is 0.9641, the efficiency is significantly higher than the joint prediction of a single gene, and the prediction efficiency is significantly improved. The specific data is as follows figure 1 and shown in Table 1.

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a maker for predicting bladder cancer chemosensitivity. The marker is a combinationof SOCS1 and CYLD genes. According to the marker for predicting the bladder cancer chemosensitivity and the marker being the combination of the SOCS1 and the CYLD genes, the jointly-predicted area under a ROC curve by the combination of the SOCS1 and the CYLD genes is 0.9641, sensitiveness reaches 92.51%, and specificity reaches 91.31%. According to the marker for predicting the bladder cancer chemosensitivity and application, sensibility of a bladder cancer patient to chemotherapy drug gemcitabine can be quickly and accurately mastered by a clinician, the foundation is laid for the clinic treatment effect, help is provided for discoveringnovel drug targets which have potential treatment values and enhance the sensibility of the chemotherapy drug gemcitabine, and good application values and prospects are achieved.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a marker for predicting chemotherapy sensitivity of bladder cancer and its application. Background technique [0002] Worldwide, bladder cancer is the second most common malignant tumor in the genitourinary system, seriously endangering human health. About 90% of bladder cancer is urothelial carcinoma, which originates from bladder epithelial cells. Invasive bladder tumors have aggressive properties in which the tumor penetrates the basal layer or invades the muscular layer. Clinically, radical cystectomy is still the most commonly used treatment for invasive bladder cancer. Despite the continuous improvement of surgical techniques, the survival rate of bladder cancer has not improved significantly in the past ten years, and the five-year tumor-specific survival rate is still about 50%. [0003] Bladder cancer is one of the most common malignant tumors of the genitourinary system....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886
CPCC12Q1/6886C12Q2600/106C12Q2600/136C12Q2600/158
Inventor 王海峰王剑松栾婷付什黄应龙
Owner 昆明医科大学第二附属医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com